Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world

Objective To assess the efficacy and safety of iGlarLixi (titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide) in patients with type 2 diabetes (T2D) living in North America (NA; USA and Canada) compared with the rest of the world (RoW).Research design and methods Post ho...

Full description

Saved in:

Bibliographic Details
Main Authors:	George Dailey, Harpreet S Bajaj, Terry Dex, Melanie Groleau, William Stager, Aaron Vinik
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2019-05-01
Series:	BMJ Open Diabetes Research & Care
Online Access:	https://drc.bmj.com/content/7/1/e000581.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prescription characteristics of the insulin glargine plus lixisenatide fixed-ratio combination in real-world clinical practice according to the Registry of Diabetes Mellitus in the Moscow Region
by: Inna V. Misnikova, et al.
Published: (2024-12-01)

Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO
by: M. B. Antsiferov, et al.
Published: (2022-05-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Real-world effectiveness and safety of fixed-ratio combination insulin glargine 100 u/ml plus lixisenatide in adults with type 2 diabetes (T2DM): subanalysis of the international, multicentre, prospective observational study SUCCESS in the Russian population
by: O. K. Vikulova, et al.
Published: (2024-11-01)

Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-12-01)

Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy
by: Pešić Milica, et al.
Published: (2007-01-01)

Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
by: Sorin Ioacara, et al.
Published: (2015-01-01)

Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine
by: Natalie Rosario, et al.
Published: (2025-03-01)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
by: Jacques Lepercq, et al.
Published: (2012-01-01)

Lantus (insulin glargin): real'nye preimushchestva i perspektivy primeneniya v pediatrii
by: Valentina Alexandrovna Peterkova, et al.
Published: (2003-09-01)

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
by: Wei Liu, et al.
Published: (2018-01-01)

Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma
by: N. B. Abramenko, et al.
Published: (2019-09-01)

Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries
by: David Beran, et al.
Published: (2025-01-01)

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
by: Elena Valer'evna Biryukova, et al.
Published: (2012-09-01)

Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
by: Natalya Nikitichna Volevodz, et al.
Published: (2013-03-01)

Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
by: Murtada Alsaif, et al.
Published: (2025-06-01)

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300
by: Oppel B.W. Greeff, et al.
Published: (2018-08-01)

Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model.
by: Ernesto Luna, et al.
Published: (2018-01-01)

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database
by: Tongtong Wang, et al.
Published: (2025-04-01)

Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice
by: Hangya Peng, et al.
Published: (2021-01-01)

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
by: Marina Vladimirovna Shestakova, et al.
Published: (2010-03-01)

Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes
by: Hiba Abdelmunim Suliman Elsheikh, et al.
Published: (2025-06-01)

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
by: Xia Zhang, et al.
Published: (2021-03-01)

Insulin glargin v lechenii sakharnogo diabeta 2 tipa: dokazatel'naya otsenka ego klinicheskoy i ekonomicheskoy effektivnosti
by: Irina Vladimirovna Glinkina
Published: (2008-12-01)

Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
by: Menghui Luo, et al.
Published: (2020-01-01)

Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study
by: Luca Degli Esposti, et al.
Published: (2019-01-01)

Development of AIDA v4.3b Diabetes Simulator: Technical Upgrade to Support Incorporation of Lispro, Aspart, and Glargine Insulin Analogues
by: Eldon D. Lehmann, et al.
Published: (2011-01-01)

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa
by: Mark T. Verryn, et al.
Published: (2025-03-01)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
by: Wen-shan Lv, et al.
Published: (2013-01-01)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
by: B. Wolnik, et al.
Published: (2020-01-01)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
by: Hernando Vargas-Uricoechea
Published: (2018-01-01)

Connectivity on fixed air route in aeronautical ad hoc networks
by: Chang-yuan LUO, et al.
Published: (2014-09-01)

Connectivity on fixed air route in aeronautical ad hoc networks
by: Chang-yuan LUO, et al.
Published: (2014-09-01)

Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial
by: Lu Yuan, et al.
Published: (2021-01-01)

Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project
by: Nick Freemantle, et al.
Published: (2020-04-01)

Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross‐sectional study
by: Pin‐Lun Tsai, et al.
Published: (2024-12-01)

Intranasal insulin enhances resting-state functional connectivity in Type 2 Diabetes.
by: Zongpai Zhang, et al.
Published: (2025-01-01)

Otsenka klinicheskogo primeneniya Lantusa (insulina glargin) v praktike raboty endokrinologicheskoy sluzhby Moskvy
by: Mikhail Borisovich Antsiferov, et al.
Published: (2005-06-01)

Changes in granule mobility and age contribute to changes in insulin secretion after desensitization or rest
by: Bastian Gaus, et al.
Published: (2021-03-01)